✦ LIBER ✦

64 Tiotropium in cystic fibrosis: Pooled analysis of phase II and III randomized, controlled trials

✍ Scribed by Geller, D.; Koker, P.; Elborn, J.S.; Le Maulf, F.; Kattenbeck, S.; Moroni-Zentgraf, P.; Ratjen, F.

Book ID: 122905113
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 68 KB
Volume: 12
Category: Article
ISSN: 1569-1993
DOI: 10.1016/S1569-1993(13)60206-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

61 Tiotropium Respimat in cystic fibrosi

61 Tiotropium Respimat in cystic fibrosis: Efficacy and safety results of phase III randomized placebo-controlled trial

✍ Ratjen, F.; Koker, P.; Geller, D.; Langellier-Cocteaux, B.; Maulf, F. Le; Katten 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Efficacy and Safety of Moxifloxacin in H

Efficacy and Safety of Moxifloxacin in Hospitalized Patients with Secondary Peritonitis: Pooled Analysis of Four Randomized Phase III Trials

✍ De Waele, Jan J.; Tellado, Jose M.; Weiss, Günter; Alder, Jeffrey; Kruesmann, Fr 📂 Article 📅 2014 🏛 Mary Ann Liebert 🌐 English ⚖ 243 KB

Venous Thromboembolic Events With Chemot

Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies

✍ Hurwitz, H. I.; Saltz, L. B.; Van Cutsem, E.; Cassidy, J.; Wiedemann, J.; Sirzen 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 159 KB

Efficacy and safety of efalizumab in pat

Efficacy and safety of efalizumab in patients with moderate to severe plaque psoriasis*1Pooled results from three phase III randomized, placebo-controlled trials

✍ NAYAK, A 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 27 KB

Efficacy of Icatibant in Laryngeal Attac

Efficacy of Icatibant in Laryngeal Attacks of Type I and II Hereditary Angioedema (HAE): A Pooled Analysis of Three Phase III Trials

✍ Lumry, W.; Ritchie, B.; Baş, M. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Safety results from a pooled analysis of

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

✍ Langley, R.G.; Papp, K.; Gottlieb, A.B.; Krueger, G.G.; Gordon, K. B.; Williams, 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB